Bone News and Research

RSS

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Vitamin K2 in Hawaiian Spirulina Pacifica

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced its Hawaiian Spirulina Pacifica® has achieved another nutritional first. Already the most nutritious Spirulina in the world, it is also a good source of Vitamin K2.

10 Dec 2009

Registered dietitians recommend vitamins and supplements for improved bone health

It wouldn't be surprising to find that registered dietitians (RDs) are among the healthiest eaters in the United States, but their healthy habits extend beyond diet. Registered dietitians demonstrate a commitment to the three pillars of health: a healthy diet, supplements and regular exercise.

10 Dec 2009

Researchers investigate bone pathology

The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.

10 Dec 2009

Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8

Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with Rituxan (rituximab) compared to chemotherapy alone.

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Dermal stem cells may be useful for treating diabetic ulcers and neurological disorders

Scientists have discovered a new type of stem cell in the skin that acts surprisingly like certain stem cells found in embryos: both can generate fat, bone, cartilage, and even nerve cells.

10 Dec 2009

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Osteologix to file an European Marketing Application for its NB S101 strontium therapy

Osteologix Inc. announced today that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix' first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis.

9 Dec 2009

Protalix Biotherapeutics completes NDA submission for taliglucerase alfa

Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher’s disease.

9 Dec 2009

European market for digestive health ingredients to reach $536.5 million in 2015

rowing consumer awareness of functional foods fuels demand and boosts product availability for digestive health ingredients in the EU. In 2008, digestive health was the largest product segment of the total EU approved functional food market, accounting for 68.0 per cent of sales.

9 Dec 2009

Novo A/S implement 10b5-1 trading plan for open market purchases of BioMimetic common stock

BioMimetic Therapeutics, Inc. and Novo A/S announced that on December 8, 2009, Novo A/S implemented a 10b5-1 trading plan, providing for open market purchases of BioMimetic common stock. Any transactions involving the Company's securities under the plan will be reported and disclosed as required by applicable securities laws.

9 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009

2009 Ward Burdick Award for UAB Director

The director of the University of Alabama at Birmingham (UAB) Center for Metabolic Bone Disease has won the 2009 Ward Burdick Award for Distinguished Service to Clinical Pathology from the American Society for Clinical Pathology (ASCP).

9 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

New regenerative therapies for heart disease being developed

Bioengineers from University of California, San Diego are developing new regenerative therapies for heart disease. The work could influence the way in which regenerative therapies for cardiovascular and other diseases are treated in the future.

9 Dec 2009

IQWiG's report on autologous stem cell transplantation for soft tissue sarcoma

Due to a lack of suitable studies, it is unclear whether patients with soft tissue sarcoma can benefit from autologous haematopoietic stem cell transplantation. With this type of therapy, some of the patient's own (autologous) stem cells are removed at a convenient time and generally re-implanted after a course of high-dose chemotherapy.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Bone News and Research

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Vitamin K2 in Hawaiian Spirulina Pacifica

Registered dietitians recommend vitamins and supplements for improved bone health

Researchers investigate bone pathology

Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Dermal stem cells may be useful for treating diabetic ulcers and neurological disorders

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Osteologix to file an European Marketing Application for its NB S101 strontium therapy

Protalix Biotherapeutics completes NDA submission for taliglucerase alfa

European market for digestive health ingredients to reach $536.5 million in 2015

Novo A/S implement 10b5-1 trading plan for open market purchases of BioMimetic common stock

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

VERTICAL Phase II trial results for NHL released

AHS annual meeting focuses on myeloma, says IMF

2009 Ward Burdick Award for UAB Director

Memgen announces positive clinical data of ISF35 with chemotherapy

New regenerative therapies for heart disease being developed

IQWiG's report on autologous stem cell transplantation for soft tissue sarcoma

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News